132 related articles for article (PubMed ID: 8172803)
1. Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron.
Childs AM; Coates AS; Cox KM; Mainwaring PN
Ann Oncol; 1994 Jan; 5(1):98. PubMed ID: 8172803
[No Abstract] [Full Text] [Related]
2. Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron.
Coates AS; Childs A; Cox K; Forsyth C; Joshua DE; McNeil E; Grygiel JJ
Ann Oncol; 1992 Nov; 3(9):719-22. PubMed ID: 1450061
[TBL] [Abstract][Full Text] [Related]
3. Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy.
Herrington JD; Kwan P; Young RR; Lagow E; Lagrone L; Riggs MW
Pharmacotherapy; 2000 Nov; 20(11):1318-23. PubMed ID: 11079280
[TBL] [Abstract][Full Text] [Related]
4. Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure.
Castle WM; Cunningham K; Kanarek BB
Ann Oncol; 1992 Nov; 3(9):773-4. PubMed ID: 1450069
[No Abstract] [Full Text] [Related]
5. Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis.
Ramamoorthy SK; Marangolo M; Durrant E; Akima S; Gottlieb DJ
Leuk Lymphoma; 2006 Apr; 47(4):747-50. PubMed ID: 16690535
[No Abstract] [Full Text] [Related]
6. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
7. Survey ranking of emetogenic control in children receiving chemotherapy.
Small BE; Holdsworth MT; Raisch DW; Winter SS
J Pediatr Hematol Oncol; 2000; 22(2):125-32. PubMed ID: 10779025
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Ng WL; Della-Fiorentina SA
Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
[TBL] [Abstract][Full Text] [Related]
9. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Berry WR; House KW; Lee JT; Plagge PB; Meshad MW; Grapski R
Semin Oncol; 1992 Dec; 19(6 Suppl 15):33-7. PubMed ID: 1485180
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Ondansetron and Lorazepam in controlling emesis associated with cytotoxic chemotherapy.
Mughal TI
Acta Oncol; 1994; 33(5):537-9. PubMed ID: 7917368
[TBL] [Abstract][Full Text] [Related]
11. Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children.
Jürgens H; McQuade B
Oncology; 1992; 49(4):279-85. PubMed ID: 1387928
[TBL] [Abstract][Full Text] [Related]
12. Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Rzepecki P; Pielichowski W; Oborska S; Barzal J; Mlot B
Transplant Proc; 2009 Oct; 41(8):3247-9. PubMed ID: 19857722
[TBL] [Abstract][Full Text] [Related]
13. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
[TBL] [Abstract][Full Text] [Related]
14. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Gralla R; Lichinitser M; Van Der Vegt S; Sleeboom H; Mezger J; Peschel C; Tonini G; Labianca R; Macciocchi A; Aapro M
Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
16. Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy.
Goldschmidt H; Salwender H; Egerer G; Kempe R; Voigt T
Anticancer Drugs; 1997 Jun; 8(5):436-44. PubMed ID: 9215605
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.
Nathan PC; Tomlinson G; Dupuis LL; Greenberg ML; Ota S; Bartels U; Feldman BM
Support Care Cancer; 2006 Mar; 14(3):268-76. PubMed ID: 16052316
[TBL] [Abstract][Full Text] [Related]
18. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
Hesketh PJ; Beck T; Uhlenhopp M; Kris MG; Hainsworth JD; Harker WG; Cohen JR; Lester E; Kessler JF; Griffen D
J Clin Oncol; 1995 Aug; 13(8):2117-22. PubMed ID: 7636556
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
Italian Group for Antiemetic Research
N Engl J Med; 2000 May; 342(21):1554-9. PubMed ID: 10824073
[TBL] [Abstract][Full Text] [Related]
20. The clinical use of ondansetron. New South Wales Therapeutic Assessment Group.
Currow DC; Noble PD; Stuart-Harris RC
Med J Aust; 1995 Feb; 162(3):145-9. PubMed ID: 7854228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
